Physician profile
Anna Van Kirk
NPI 1730868712
$3,021.30
in general payments reported to CMS, 2019-2025
25 companies · $1,322 in 2025
The $1,322 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $371 · 2024: $1,328 · 2025: $1,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,921 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,921.31 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $530.20 | 2023-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $315.78 | 2024-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $277.15 | 2023-2025 | Farxiga, Brilinta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $276.08 | 2024-2025 | Lifevest |
| Novo Nordisk INC | $200.89 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lexicon Pharmaceuticals, INC. | $196.05 | 2024 | |
| Amgen INC. | $188.15 | 2023-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $132.61 | 2023-2024 | Xarelto |
| Heartflow, INC. | $118.21 | 2025 | |
| Daiichi Sankyo INC. | $117.43 | 2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $103.51 | 2023-2024 | |
| Scpharmaceuticals INC. | $95.85 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.81 | 2023-2025 | |
| Corcept Therapeutics | $60.58 | 2024-2025 | Korlym |
| Merck Sharp & Dohme LLC | $56.32 | 2024-2025 | Verquvo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $54.18 | 2024-2025 | Opsumit, Uptravi |
| Sanofi-Aventis U.S. LLC | $41.44 | 2024 | |
| Mylan Specialty L.P. | $39.90 | 2023-2024 | Yupelri |
| Bridgebio Pharma, INC. | $31.89 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $28.41 | 2024 | Arcalyst |
| Boston Scientific Corporation | $20.59 | 2025 | Watchman |
| Azurity Pharmaceuticals, INC. | $19.77 | 2023 | Edarbi |
| Glaxosmithkline, LLC. | $17.26 | 2025 | Shingrix, Arexvy |
| Exact Sciences Corporation | $16.81 | 2025 | Cologuard Collection Kit |
| Kiniksa Pharmaceuticals, LTD. | $15.43 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Van Kirk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.